Company intelligence / Profile preview

NewVac

Khimki/Moscow area, Moscow Region/Moscow Oblast, Russianewvac-llc.com ↗

Ownership: Private
Development stage: Commercial

Overview

NewVac has completed a Phase II clinical trial of quisinostat, an oral selective histone deacetylase inhibitor, in combination with chemotherapy for platinum-resistant ovarian cancer. The study demonstrated a high objective response rate of 51.6%, exceeding protocol expectations, with favorable safety and tolerability. Median progression-free survival was reported at seven months. The company is also developing personalized therapeutic vaccines and other oncology assets.

Therapeutic areas: OncologyCardiovascular
Modalities: Small moleculeVaccine
Industry: Biotech

Drug pipeline

1 asset

quisinostat

Partnerships

Janssen Pharmaceutica NV / Johnson & Johnson Group – license/co-development agreement for quisinostatAgenus – collaboration on personalized vaccines

Beyond the preview

Go deeper on NewVac.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NewVac.

Explore the full profile